Aadi Bioscience (NASDAQ:AADI) Downgraded by TD Cowen

TD Cowen lowered shares of Aadi Bioscience (NASDAQ:AADI) from a buy rating to a hold rating in a research report sent to investors on Wednesday, MarketBeat reports.

Separately, HC Wainwright reaffirmed a neutral rating on shares of Aadi Bioscience in a research note on Tuesday, May 14th.

Aadi Bioscience Trading Up 1.9 %

NASDAQ AADI opened at $1.58 on Wednesday. Aadi Bioscience has a 1 year low of $1.21 and a 1 year high of $7.24. The company has a market cap of $38.80 million, a PE ratio of -0.62 and a beta of 0.69. The stock’s 50-day moving average price is $1.51 and its two-hundred day moving average price is $1.80.

Aadi Bioscience (NASDAQ:AADI) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.17. Aadi Bioscience had a negative net margin of 288.72% and a negative return on equity of 61.83%. The firm had revenue of $6.18 million during the quarter, compared to analyst estimates of $6.33 million. During the same quarter last year, the business posted ($0.67) EPS. Research analysts forecast that Aadi Bioscience will post -2.54 EPS for the current fiscal year.

Insider Activity

In other Aadi Bioscience news, Chairman Neil Desai sold 31,348 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1.45, for a total value of $45,454.60. Following the completion of the sale, the chairman now directly owns 1,260,195 shares of the company’s stock, valued at $1,827,282.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 52,415 shares of company stock worth $76,151 in the last three months. 37.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Aadi Bioscience during the second quarter valued at approximately $37,000. Marquette Asset Management LLC acquired a new position in Aadi Bioscience during the 1st quarter worth $135,000. Acuitas Investments LLC boosted its holdings in Aadi Bioscience by 10.8% during the second quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock valued at $515,000 after acquiring an additional 34,344 shares during the period. Finally, Decheng Capital LLC bought a new position in shares of Aadi Bioscience in the fourth quarter worth about $1,063,000. 52.08% of the stock is owned by institutional investors.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.